Clinical Trials Directory

Trials / Completed

CompletedNCT01964599

Potato Fiber and Gastrointestinal Function: Phase 3

Potato Fiber and Gastrointestinal Function: Phase 3 (Grant #94521)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
University of Florida · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The primary physiological impacts of fiber intake include the gastrointestinal effects of stool bulking, increased stool frequency and decreased gastrointestinal transit time (GTT). Fermentation of resistant starches by microbiota increases bacterial numbers, which increases fecal bulk and may impact frequency and transit time. The purpose of this study is to determine the effects of resistant potato starches (potato fiber) on stool frequency, transit time and microbiota in healthy individuals.

Detailed description

Potato fiber (PF-RS, PF-RO1 and PF-RO2), supplemented in the diet of healthy individuals (n=60; 20 per group) and providing 30 g per day of fiber, will result in a significant changes in gastrointestinal function and microbiota profile. Objectives: 1. To determine the effect of potato fibers on stool frequency, gastrointestinal transit time and gastrointestinal symptoms. 2. To determine the effect of potato fibers on microbial diversity in healthy individuals.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPF-RSn=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
DIETARY_SUPPLEMENTPF-RO1n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
DIETARY_SUPPLEMENTPF-RO2n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
DIETARY_SUPPLEMENTControl

Timeline

Start date
2014-01-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2013-10-17
Last updated
2017-01-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01964599. Inclusion in this directory is not an endorsement.